RxDoctor Payments Data

Georges Kaddissi, MD

Cardiovascular Disease · Haddon Heights, NJNPI 1821040478

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $9,810 of the $14,978 with a category attached, or 65.5%. 41 manufacturers reported payments, led by Abbott at 36.8% of the total. Reporting peaked in 2024 at $4,265 and has fallen 61.4% since, to $1,646 in 2025.

$14,978in general payments, 2019–2025

Across 389 payments — averaging $38.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$6K
  • Edwards Lifesciences$3K
  • Medtronic$3K
  • Boston Scientific$492
  • Pfizer$366
  • Amgen$268
  • plus $3K from 35 others
$31,251in research payments, 2019–2025

Across 19 payments — averaging $1644.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$18K
  • Cordis Corporation$13K
  • Boston Scientific$484

What the payments were for

  • Travel & lodging$5,16735%
  • Food & beverage$9,81065%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,978 in reported general payments places this provider in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey →

Medicare billing

Part B allowed, 2024
$340,450
Medicare patients
836
Services billed
2,786

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban63$88,618
EntrestoSacubitril/Valsartan33$42,689
XareltoRivaroxaban18$27,631
FarxigaDapagliflozin Propanediol15$10,604
Repatha SureclickEvolocumab12$8,585
Metoprolol Succinate245$3,829
Rosuvastatin Calcium209$3,484
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide49$2,541
Atorvastatin Calcium183$1,778
Ezetimibe38$1,134
Irbesartan23$756
Valsartan19$679
Amlodipine Besylate81$670
ClopidogrelClopidogrel Bisulfate43$609
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide23$548

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$366$88,61863 claims
NovartisEntresto$265$42,68933 claims
Johnson & JohnsonXarelto$186$27,63118 claims
AstraZenecaFarxiga$241$10,60415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Haddon Heights

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →